Last reviewed · How we verify
c-PDT
c-PDT is a photodynamic therapy approach that uses a photosensitizing agent activated by light to generate reactive oxygen species and destroy target cells.
c-PDT is a photodynamic therapy approach that uses a photosensitizing agent activated by light to generate reactive oxygen species and destroy target cells. Used for Actinic keratosis, Non-melanoma skin cancer.
At a glance
| Generic name | c-PDT |
|---|---|
| Also known as | Metvix c-PDT, Metvix placebo c-PDT |
| Sponsor | Galderma R&D |
| Drug class | Photodynamic therapy agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Photodynamic therapy (PDT) involves administration of a photosensitizer that accumulates in target tissues, followed by light activation at a specific wavelength. This activation generates singlet oxygen and other reactive oxygen species that cause direct cell death and vascular damage. The 'c-' prefix likely indicates a modified or optimized formulation by Galderma for dermatological applications.
Approved indications
- Actinic keratosis
- Non-melanoma skin cancer
Common side effects
- Phototoxicity/photosensitivity
- Erythema
- Edema
- Pain or burning at treatment site
- Crusting or scaling
Key clinical trials
- Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT) (NA)
- A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT (PHASE2)
- Clinical and Microbiological Evaluation of Laser Therapy in the Treatment of Periodontal Disease in Stages III and IV (NA)
- Cosiporfin Sodium for Injection Photodynamic Therapy (PHASE2)
- Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses (PHASE2)
- Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C) (PHASE3)
- Evaluation of Chlorhexidine Gel Associated with Photodynamic Therapy in the Treatment of Chronic Periodontitis in Type 2 Diabetics (NA)
- Comparing Photodisinfection of Chitosan NP Enriched ICG Over ICG as Adjunct to OFD: RCT (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- c-PDT CI brief — competitive landscape report
- c-PDT updates RSS · CI watch RSS
- Galderma R&D portfolio CI